Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | CLK3 | P49761 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191614 | 0.85 | RIPK1 (0.34) | CDK2RIPK1CLK2CLK3DYRK1A | |
| SCHEMBL21191525 | 0.82 | RIPK1 (0.36) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL25942800 | 0.79 | RIPK1 (0.48) | CDK2RIPK1CLK2CLK3DYRK1A | |
| SCHEMBL26189379 | 0.73 | NPC1 (0.36) | RIPK1APP | |
| SCHEMBL19222408 | 0.71 | RIPK1 (0.39) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL25937022 | 0.71 | RIPK1 (0.54) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL18583291 | 0.67 | RIPK1 (0.42) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL18673050 | 0.65 | RIPK1 (0.41) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL21755111 | 0.63 | RIPK1 (0.53) | RIPK1CLK2CLK3DYRK1ACCNB2 | |
| SCHEMBL20622229 | 0.63 | GSK3B (0.36) | CDK2RIPK1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210008057-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008057-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | CCNT1 25/4885CCNA2 20/4885CDK2 10/4885 |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | CCNT1 25/4885CCNA2 20/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.